Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases Alzheimer’s disease (AD) risk. In mouse models of amyloid β (Aβ) accumulation, defective TREM2 function affects microglial response to Aβ plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate for AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AL002 (27) is a TREM2-specific monoclonal antibody that activates TREM2 to enhance microglial function, thereby reducing Aβ plaque formation and attenuating neurite dystrophy.474”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [474]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“enhancing TREM2 signaling by TREM2 agonist antibody, direct delivery of the TREM2 gene, or stimulating other pathways to increase TREM2 expression in the brains of AD mice enhanced Aβ phagocytosis and improved cognitive behaviors.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence has shown that TREM2 activation increased Aβ phagocytosis, relieved neuroinflammation, and improved cognitive behavior in AD mouse models.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an AD mouse model, administration of AL002c, a variant of the AL002 antibody, attenuated tau plaques and neurite dystrophy, improved behavior, and reduced microglial inflammation.537”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [537]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The opposite phenotypes observed in PLCG2 KO iMGs and Plcγ2-P522R KI mice also support the notion to therapeutically stimulate TREM2 functions [6, 16, 17, 43].”
From The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Self-citationDissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“In this model, plaques become clearly detectable at 3–4 mo of age and continue to grow for several months (Oakley et al., 2006).”
MethodAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Cited by
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
The Semantics of Microglia Activation: Neuroinflammation, Homeostasis, and Stress
Woodburn, S. C., Bollinger, J. L., & Wohleb, E. S. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02309-6 · Cited by 783
Macrophages in health and disease
Park, M. D., Silvin, A., Ginhoux, F., & Merad, M. (2022) · Cell · doi:10.1016/j.cell.2022.10.007 · Cited by 644
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Self-citationMicroglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
“The administration of AL002c to AD models slightly, but significantly, reduced filamentous Aβ plaques and neurites dystrophy, promoting phagocytic activity of microglia (Wang et al., 2020).”
BackgroundAlzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2025) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 410
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways
Wang, S., Sudan, R., Peng, V., Zhou, Y., Du, S., Yuede, C. M., Lei, T., Hou, J., Cai, Z., Cella, M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.033 · Cited by 471
Self-citationColonna, M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00837-1 · Cited by 394
Self-citationEmerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
McQuade, A., Kang, Y. J., Hasselmann, J., Jairaman, A., Sotelo, A., Coburn, M., Shabestari, S. K., Chadarevian, J. P., Fote, G., Tu, C. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19227-5 · Cited by 361
Cai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351
Neuroinflammation across neurological diseases
Shi, F.-D., & Yong, V. W. (2025) · Science · doi:10.1126/science.adx0043 · Cited by 274
Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice?
Chen, Y., & Colonna, M. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202717 · Cited by 339
Self-citationThe good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology
Lee, S.-H., Meilandt, W. J., Xie, L., Gandham, V. D., Ngu, H., Barck, K. H., Rezzonico, M. G., Imperio, J., Lalehzadeh, G., Huntley, M. A., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.02.010 · Cited by 300
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease
Rajesh, Y., & Kanneganti, T.-D. (2022) · Cells · doi:10.3390/cells11121885 · Cited by 262
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266
TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer
Park, M. D., Reyes-Torres, I., LeBerichel, J., Hamon, P., LaMarche, N. M., Hegde, S., Belabed, M., Troncoso, L., Grout, J. A., Magen, A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01475-4 · Cited by 251
Self-citationvan Lengerich, B., Zhan, L., Xia, D., Chan, D., Joy, D., Park, J. I., Tatarakis, D., Calvert, M., Hummel, S., Lianoglou, S., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01240-0 · Cited by 233
Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
Lewcock, J. W., Schlepckow, K., Di Paolo, G., Tahirovic, S., Monroe, K. M., & Haass, C. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.029 · Cited by 221
Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 202
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
Okano, H., & Morimoto, S. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.01.007 · Cited by 202
Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis
Patterson, M. T., Firulyova, M. M., Xu, Y., Hillman, H., Bishop, C., Zhu, A., Hickok, G. H., Schrank, P. R., Ronayne, C. E., Caillot, Z., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00354-3 · Cited by 180
Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery
Pardridge, W. M. (2020) · Pharmaceuticals · doi:10.3390/ph13110394 · Cited by 194
Targeting neuroinflammation in Alzheimer’s disease: from mechanisms to clinical applications
Liu, Y., Si, Z.-Z., Zou, C.-J., Mei, X., Li, X.-F., Luo, H., Shen, Y., Hu, J., Li, X.-X., & Wu, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.353484 · Cited by 182
Claes, C., Danhash, E. P., Hasselmann, J., Chadarevian, J. P., Shabestari, S. K., England, W. E., Lim, T. E., Hidalgo, J. L. S., Spitale, R. C., Davtyan, H., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00473-0 · Cited by 197
The role of innate immune genes in Alzheimer's disease
Griciuc, A., & Tanzi, R. E. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000911 · Cited by 192
TREM2 dependent and independent functions of microglia in Alzheimer’s disease
Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191
Self-citationUpdates on mouse models of Alzheimer’s disease
Zhong, M. Z., Peng, T., Duarte, M. L., Wang, M., & Cai, D. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00712-0 · Cited by 189
“Recently, a study demonstrated that up-regulation of TREM2 by AL002c reduced plaque burden, decreased neurite dystrophy, rescued abnormal behaviors such as risk-taking and exploratory drive, and attenuated microglial inflammatory responses [142].”
BackgroundTargeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 193
Origins, Biology, and Diseases of Tissue Macrophages
Cox, N., Pokrovskii, M., Vicario, R., & Geissmann, F. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-111748 · Cited by 163
Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease
van Olst, L., Simonton, B., Edwards, A. J., Forsyth, A. V., Boles, J. S., Jamshidi, P., Watson, T. H., Shepard, N., Krainc, T., Argue, B. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03574-1 · Cited by 186
Long, H., Simmons, A., Mayorga, A., Burgess, B., Nguyen, T., Budda, B., Rychkova, A., Rhinn, H., Tassi, I., Ward, M., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01599-1 · Cited by 124
Self-citationChronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading
Jain, N., Lewis, C. A., Ulrich, J. D., & Holtzman, D. M. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220654 · Cited by 146
Shi, Q., Chang, C., Saliba, A., & Bhat, M. A. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.2427-21.2022 · Cited by 127
Zhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141
“CD68, the phagocytic marker of microglia, is frequently used to study the phagocytic status of plaque proximal microglia (20, 30, 43).”
BackgroundResultInfluentialJiang, S., Cai, G., Yang, Z., Shi, H., Zeng, H., Ye, Q., Hu, Z., & Wang, Z. (2024) · ACS Nano · doi:10.1021/acsnano.3c13150 · Cited by 145
Microglia in Alzheimer’s Disease: A Target for Therapeutic Intervention
Zhang, G., Wang, Z., Hu, H., Zhao, M., & Sun, L. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.749587 · Cited by 128
Fang, C., Zhong, R., Lu, S., Yu, G., Liu, Z., Yan, C., Gao, J., Tang, Y., Wang, Y., Zhao, Q., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91519 · Cited by 144
Molecular and metabolic heterogeneity of astrocytes and microglia
Hasel, P., Aisenberg, W. H., Bennett, F. C., & Liddelow, S. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.006 · Cited by 138
Soluble TREM2: Innocent bystander or active player in neurological diseases?
Filipello, F., Goldsbury, C., You, S. F., Locca, A., Karch, C. M., & Piccio, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105630 · Cited by 134
Ellwanger, D. C., Wang, S., Brioschi, S., Shao, Z., Green, L., Case, R., Yoo, D., Weishuhn, D., Rathanaswami, P., Bradley, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017742118 · Cited by 134
Self-citationMicroglia in Alzheimer’s Disease in the Context of Tau Pathology
Perea, J. R., Bolós, M., & Avila, J. (2020) · Biomolecules · doi:10.3390/biom10101439 · Cited by 123
TREM2: Potential therapeutic targeting of microglia for Alzheimer's disease
Li, Y., Xu, H., Wang, H., Yang, K., Luan, J., & Wang, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115218 · Cited by 126
Self-citationAlzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Cummings, J. L., Osse, A. M. L., & Kinney, J. W. (2023) · Drugs · doi:10.1007/s40265-023-01938-w · Cited by 139
Schlepckow, K., Morenas-Rodríguez, E., Hong, S., & Haass, C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00247-8 · Cited by 114
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124
“TREM2 is a membrane protein predominantly expressed on microglia in the CNS [35, 161, 236], playing critical roles in the wide-ranging microglial functions, including proliferation, differentiation, phagocytosis, metabolism, survival, lipid handling and inflammatory responses [38, 40, 237–240].”
TREM2 regulates microglial lipid droplet formation and represses post-ischemic brain injury
Wei, W., Zhang, L., Xin, W., Pan, Y., Tatenhorst, L., Hao, Z., Gerner, S. T., Huber, S., Juenemann, M., Butz, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115962 · Cited by 122
TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma
Sun, R., Han, R., McCornack, C., Khan, S., Tabor, G. T., Chen, Y., Hou, J., Jiang, H., Schoch, K. M., Mao, D. D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade3559 · Cited by 119
The role of the immune system in Alzheimer’s disease
Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 125
Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
Zhao, N., Qiao, W., Li, F., Ren, Y., Zheng, J., Martens, Y. A., Wang, X., Li, L., Liu, C.-C., Chen, K., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20212479 · Cited by 111
Ausejo‐Mauleon, I., Labiano, S., de la Nava, D., Laspidea, V., Zalacaín, M., Marrodán, L., García-Moure, M., González-Huarriz, M., Hervás-Corpión, I., Dhandapani, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.001 · Cited by 118
Tong, B., Ba, Y., Li, Z., Yang, C., Su, K., Qi, H., Zhang, D., Liu, X., Wu, Y., Chen, Y., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106505 · Cited by 117
The gut microbiome modulates the transformation of microglial subtypes
Huang, Y., Wu, J., Zhang, H., Li, Y., Wen, L., Tan, X., Cheng, K., Liu, Y., Pu, J., Liu, L., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02017-y · Cited by 111
Neuroinflammation, Its Role in Alzheimer's Disease and Therapeutic Strategies
Király, M., Foss, J. F., & Giordano, T. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.109 · Cited by 121
A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer’s disease
Yoo, Y., Neumayer, G., Shibuya, Y., Mader, M. M.-D., & Wernig, M. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.07.006 · Cited by 109
Li, T., Lu, L., Pember, E., Li, X., Zhang, B., & Zhu, Z. (2022) · Cells · doi:10.3390/cells11121925 · Cited by 104
Wang, M., Song, W., Chen, M., Wang, Q., Zhou, X., Xu, P., Krek, A., Yoon, Y., Ho, L., Orr, M. E., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00517-z · Cited by 110
Microbiota and Microglia Interactions in ASD
Davoli-Ferreira, M., Thomson, C. A., & McCoy, K. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676255 · Cited by 88
Noh, M., Kwon, H. S., Kwon, M., Nahm, M., Jin, H. K., Bae, J., & Kim, S. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00867-4 · Cited by 97
Neuroinflammation as a Potential Therapeutic Target in Alzheimer’s Disease
Liu, P., Wang, Y., Sun, Y., & Peng, G. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s357558 · Cited by 89
Moutinho, M., Puntambekar, S. S., Tsai, A. P., Coronel, I., Lin, P. B., Casali, B. T., Martinez, P., Oblak, A. L., Lasagna-Reeves, C. A., Lamb, B. T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7634 · Cited by 92
TREM2 and sTREM2 in Alzheimer’s disease: from mechanisms to therapies
Zhang, L., Xiang, X., Li, Y., Bu, G., & Chen, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00834-z · Cited by 97
Kamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., S, S., Singh S, A., & Prajapati, B. G. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.005 · Cited by 90
“AL002c was found to modulate behavior and reduce neuroinflammatory responses, particularly in areas with branched A β fibrils and A β aggregates, which contribute to axonal damage and neurite dystrophy (Wang et al., 2020b).”
Microglia heterogeneity, modeling and cell-state annotation in development and neurodegeneration
Fumagalli, L., Nazlie Mohebiany, A., Premereur, J., Polanco Miquel, P., Bijnens, B., Van de Walle, P., Fattorelli, N., & Mancuso, R. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01931-4 · Cited by 90
Reifschneider, A., Robinson, S., van Lengerich, B., Gnörich, J., Logan, T., Heindl, S., Vogt, M. A., Weidinger, E., Riedl, L., Wind, K., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2021109108 · Cited by 89
Diet-dependent regulation of TGFβ impairs reparative innate immune responses after demyelination
Bosch-Queralt, M., Cantuti-Castelvetri, L., Damkou, A., Schifferer, M., Schlepckow, K., Alexopoulos, I., Lütjohann, D., Klose, C., Vaculčiaková, L., Masuda, T., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00341-7 · Cited by 88
Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease
Kimura, K., Subramanian, A., Yin, Z., Khalilnezhad, A., Wu, Y., He, D., Dixon, K. O., Chitta, U. K., Ding, X., Adhikari, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08852-z · Cited by 85
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions
Takalo, M., Wittrahm, R., Wefers, B., Parhizkar, S., Jokivarsi, K., Kuulasmaa, T., Mäkinen, P., Martiskainen, H., Wurst, W., Xiang, X., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00402-7 · Cited by 94
Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability—Brief Report
Patterson, M. T., Xu, Y., Hillman, H., Osinski, V., Schrank, P. R., Kennedy, A. E., Barrow, F., Zhu, A., Tollison, S., Shekhar, S., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320797 · Cited by 86
Self-citationLista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81
“One such investigational therapy is AL002, a humanized monoclonal IgG1 antibody that enhances TREM-2 signaling to improve microglia survival and proliferation [161].”
BackgroundFruhwürth, S., Zetterberg, H., & Paludan, S. R. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578342 · Cited by 74
Neuroinflammatory Biomarkers in Alzheimer’s Disease: From Pathophysiology to Clinical Implications
Roveta, F., Bonino, L., Piella, E. M., Rainero, I., & Rubino, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211941 · Cited by 89
Engineering antibody and protein therapeutics to cross the blood–brain barrier
Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 90
Pagotto, G. L. D. O., Santos, L. M. O. D., Osman, N., Lamas, C. B., Laurindo, L. F., Pomini, K. T., Guissoni, L. M., Lima, E. P. D., Goulart, R. D. A., Catharin, V. M. C. S., et al. (2024) · Antioxidants · doi:10.3390/antiox13060651 · Cited by 67
Yoo, J., Lee, J., Ahn, B., Han, J., & Lim, M. H. (2025) · Chemical Science · doi:10.1039/d4sc06762b · Cited by 80
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia
Bhattacherjee, A., Jung, J., Zia, S., Ho, M., Eskandari-Sedighi, G., St. Laurent, C. D., McCord, K. A., Bains, A., Sidhu, G., Sarkar, S., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00443-6 · Cited by 75
Danger-Sensing/Patten Recognition Receptors and Neuroinflammation in Alzheimer’s Disease
Chiarini, A., Armato, U., Hu, P., & Prà, I. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239036 · Cited by 81
Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice
Schoch, K. M., Ezerskiy, L. A., Morhaus, M. M., Bannon, R. N., Sauerbeck, A. D., Shabsovich, M., Jafar-nejad, P., Rigo, F., & Miller, T. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100356118 · Cited by 78
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 88
What are activated and reactive glia and what is their role in neurodegeneration?
Bennett, M. L., & Viaene, A. N. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105172 · Cited by 77
Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy
Ye, J., Wan, H., Chen, S., & Liu, G. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385847 · Cited by 80
Melchiorri, D., Merlo, S., Micallef, B., Borg, J.-J., & Dráfi, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1196413 · Cited by 70
Macrophage reprogramming for therapy
Bart, V. M. T., Pickering, R. J., Taylor, P. R., & Ipseiz, N. (2021) · Immunology · doi:10.1111/imm.13300 · Cited by 78
Lodder, C., Scheyltjens, I., Stancu, I. C., Botella Lucena, P., Gutiérrez de Ravé, M., Vanherle, S., Vanmierlo, T., Cremers, N., Vanrusselt, H., Brône, B., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01204-8 · Cited by 71
AmeliMojarad, M., & AmeliMojarad, M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14856 · Cited by 73
Immune mechanisms and shared immune targets in neurodegenerative diseases
Weiner, H. L. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01046-7 · Cited by 73
Exploring the Impact of TREM2 in Tumor-Associated Macrophages
Khantakova, D., Brioschi, S., & Molgora, M. (2022) · Vaccines · doi:10.3390/vaccines10060943 · Cited by 75
Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies
Sun, Z., Zhang, X., So, K.-F., Jiang, W., & Chiu, K. (2024) · Biomolecules · doi:10.3390/biom14070833 · Cited by 71
Microglial Function and Regulation during Development, Homeostasis and Alzheimer’s Disease
Casali, B. T., & Reed-Geaghan, E. G. (2021) · Cells · doi:10.3390/cells10040957 · Cited by 78
Microglia, Trem2, and Neurodegeneration
Shi, Q., Gutierrez, R. A., & Bhat, M. A. (2025) · The Neuroscientist · doi:10.1177/10738584241254118 · Cited by 69
“In line with this finding, other studies have shown that two monoclonal antibodies, AL002c and AL002a (Price and others 2020; Wang and others 2020), tailored for human and mouse Trem2, respectively, have been confirmed to ameliorate A β pathology in vivo, supporting the therapeutic potential of…”
Alzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 74
Treatment of Radiation‐Induced Brain Necrosis
Yang, X., Ren, H., & Fu, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/4793517 · Cited by 73
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 78
The Role of Microglia in the Development of Neurodegenerative Diseases
Lee, J., Chun, W., Lee, H. J., Kim, S., Min, J., Kim, D.-Y., Kim, M.-O., Ryu, H. W., & Lee, S. U. (2021) · Biomedicines · doi:10.3390/biomedicines9101449 · Cited by 67
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
Pardridge, W. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1227816 · Cited by 67
Magno, L., Bunney, T. D., Mead, E., Svensson, F., & Bictash, M. N. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00436-5 · Cited by 64
Metadata
- Authors
- Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., Ibrahim, A., Rhinn, H., Tassi, I., Rosenthal, A., Schwabe, T., & Colonna, M.
- Affiliations
- Washington University in St. Louis (US)
- Alector (United States) (US)
- Corresponding author
- Schwabe, Tina
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-06-24
- Volume
- 217
- Issue
- 9
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7478730
- OpenAlex
- W3037497912
- Cited by
- 549
- References
- 41
- Citations by year
- 2026: 106 · 2025: 115 · 2024: 101 · 2023: 93 · 2022: 64 · 2021: 52 · 2020: 18
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (RF1AG05148501, R21 AG059176, RF1 AG059082)
- Cure Alzheimer’s Fund
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- TREM2, Alzheimer's disease, microglial proliferation, amyloid plaques, microglial inflammation, transgenic mouse model, single-cell RNA sequencing, cerebrospinal fluid biomarkers, immunotherapy
- MeSH terms
- Alzheimer Disease, Animals, Antibodies, Monoclonal, Anxiety, Blood-Brain Barrier, Disease Models, Animal, Humans, Membrane Glycoproteins, Mice, Inbred C57BL, Mice, Transgenic, Protein Conformation, Receptors, Immunologic, Solubility, Signal Transduction, Biomarkers, Amyloid beta-Peptides, Neurites, Microglia, Cell Proliferation, Osteopontin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.